FDA approves Recordati's Carbaglu
This article was originally published in Scrip
Executive Summary
The US FDA has approved Recordati's Carbaglu (carglumic acid) tablets for the treatment of acute hyperammonaemia caused by the rare genetic hepatic enzyme N-acetylglutamate synthase deficiency (NAGS deficiency) and as maintenance therapy for chronic hyperammonaemia due to NAGS deficiency.